NASDAQ:HROWHarrow Health Stock Price, Forecast & News

Harrow Health's stock was trading at $4.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HROW stock has increased by 25.0% and is now trading at $5.95. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harrow Health.

Harrow Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Harrow Health.

Harrow Health (NASDAQ:HROW) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.45. The company earned $11.82 million during the quarter, compared to the consensus estimate of $10.14 million. Harrow Health had a negative net margin of 47.54% and a negative return on equity of 32.90%. View Harrow Health's earnings history.

2 brokerages have issued 1 year price objectives for Harrow Health's shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate Harrow Health's stock price to reach $12.50 in the next year. This suggests a possible upside of 110.1% from the stock's current price. View analysts' price targets for Harrow Health.

News articles about HROW stock have been trending negative on Saturday, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Harrow Health earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutHarrow Health.

Harrow Health saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,390,000 shares, an increase of 13.0% from the April 30th total of 1,230,000 shares. Based on an average daily trading volume, of 176,500 shares, the days-to-cover ratio is presently 7.9 days. Currently, 5.9% of the shares of the stock are sold short. View Harrow Health's Current Options Chain.

Some companies that are related to Harrow Health include Dynavax Technologies (DVAX), Trillium Therapeutics (TRIL), Frequency Therapeutics (FREQ), Radius Health (RDUS), Aprea Therapeutics (APRE), Athersys (ATHX), Urogen Pharma (URGN), Zafgen (ZFGN), Basilea Pharmaceutica (BPMUF), Viking Therapeutics (VKTX), Atreca (BCEL), AnaptysBio (ANAB), Crinetics Pharmaceuticals (CRNX), Corbus Pharmaceuticals (CRBP) and Clovis Oncology (CLVS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include Corbus Pharmaceuticals (CRBP), Mustang Bio (MBIO), QuickLogic (QUIK), Amarin (AMRN), Canopy Growth (CGC), Crispr Therapeutics (CRSP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Adamis Pharmaceuticals (ADMP) and Agile Therapeutics (AGRX).

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Harrow Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (2.42%), BlackRock Inc. (1.83%), Cadence Capital Management LLC (0.90%), Geode Capital Management LLC (0.73%), Morgan Stanley (0.48%) and Bank of New York Mellon Corp (0.42%). Company insiders that own Harrow Health stock include Opaleye Management Inc and Robert J Kammer. View institutional ownership trends for Harrow Health.

HROW stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Squarepoint Ops LLC, Morgan Stanley, Acadian Asset Management LLC, Russell Investments Group Ltd., Cadence Capital Management LLC, Geode Capital Management LLC, and Bank of New York Mellon Corp. View insider buying and selling activity for Harrow Health.

HROW stock was bought by a variety of institutional investors in the last quarter, including Westside Investment Management Inc., Jane Street Group LLC, Advisor Group Holdings Inc., Citigroup Inc., Wells Fargo & Company MN, and BlackRock Inc.. View insider buying and selling activity for Harrow Health.

Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HROW stock can currently be purchased for approximately $5.95.

Harrow Health has a market capitalization of $152.44 million and generates $51.17 million in revenue each year. The company earns $170,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

The official website for Harrow Health is www.harrowinc.com.

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company can be reached via phone at 615-733-4730 or via email at [email protected]